# VOICE-Early Response to Vedolizumab and IL-23 Antagonists in Participants With Crohn's Disease: A Prospective Observational Study

> **NCT06249555** · — · RECRUITING · sponsor: **Alimentiv Inc.** · enrollment: 300 (estimated)

## Conditions studied

- Crohn's Disease

## Interventions

- **DRUG:** Vedolizumab (VDZ)
- **DRUG:** Ustekinumab (UST)
- **DRUG:** Risankizumab (RISA)
- **DRUG:** Guselkumab (GUS)
- **DRUG:** Mirikizumab (MIR)

## Key facts

- **NCT ID:** NCT06249555
- **Lead sponsor:** Alimentiv Inc.
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-20
- **Primary completion:** 2026-06
- **Final completion:** 2026-12
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2026-02-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06249555

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06249555, "VOICE-Early Response to Vedolizumab and IL-23 Antagonists in Participants With Crohn's Disease: A Prospective Observational Study". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06249555. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*